// App-Quantinova.ai

504 : Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are superior to CA 15-3 in predicting tumor burden, patients response to treatment and overall survival (OS) rates in metastatic breast cancer patients from Egypt

Researchers

Presenter

  • Abdel-Rahman N. Zekri

Principal Investigators

  • Abeer A. Bahnassy

Medical Centers

  • National Cancer Inst. Cairo Univ., Cairo, Egypt.

Locations

  • Egypt

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Cancer antigen 15-3

  • p53

  • Circulating tumor cells

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved